Are questions regarding psychological distress or psychiatric disorders in patients with palliative care needs a reason to consult the palliative care team in a university medical centre in the Netherlands?
The association of having a monitoring or blunting coping style with psychological distress, health-related quality of life and satisfaction with healthcare in gastrointestinal stromal tumour (GIST) patients.
Autorzy:
van de Wal D; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. van Doorn B; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. den Hollander D; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. Desar IME; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands. Oosten AW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. ReynersAKL; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Steeghs N; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Pharmacology, The Netherlands Cancer Institute, The Netherlands. van der Graaf WTA; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Husson O; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Surgical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, The Netherlands.
Measurement and documentation of quality indicators for the end-of-life care of hospital patients a nationwide retrospective record review study.
Autorzy:
Bijnsdorp FM; Nivel, Netherlands Institute For Health Services Research, Utrecht, the Netherlands. Schouten B; Department Of Public And Occupational Health, Amsterdam Umc, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, P/O Box 7057, Amsterdam, MB, 1007, the Netherlands. . ReynersAKL; Department of Medical Oncology, Center of Expertise in Palliative Care, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands. Wagner C; Nivel, Netherlands Institute For Health Services Research, Utrecht, the Netherlands.; Department Of Public And Occupational Health, Amsterdam Umc, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, P/O Box 7057, Amsterdam, MB, 1007, the Netherlands. Francke AL; Nivel, Netherlands Institute For Health Services Research, Utrecht, the Netherlands.; Department Of Public And Occupational Health, Amsterdam Umc, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, P/O Box 7057, Amsterdam, MB, 1007, the Netherlands. van Schoten SM; Department Of Public And Occupational Health, Amsterdam Umc, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, P/O Box 7057, Amsterdam, MB, 1007, the Netherlands.
Pokaż więcej
Źródło:
BMC palliative care [BMC Palliat Care] 2023 Nov 08; Vol. 22 (1), pp. 174. Date of Electronic Publication: 2023 Nov 08.
The feasibility of a Bayesian network model to assess the probability of simultaneous symptoms in patients with advanced cancer.
Autorzy:
van der Stap L; Center of Expertise in Palliative Care, Leiden University Medical Center, Albinusdreef 2, PO box 9600, 2300 RC, Leiden, The Netherlands. . van Haaften MF; Department of Radiology and Nuclear Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands. van Marrewijk EF; Department of BioMechanical Engineering, Faculty of Mechanical, Maritime and Materials Engineering, Delft University of Technology, Delft, The Netherlands. de Heij AH; Center of Expertise for Palliative Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Jansen PL; Faculty of Medicine, Leiden University Medical Center, Leiden, The Netherlands. Burgers JMN; Faculty of Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands. Sieswerda MS; Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands.; Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. Los RK; Department of Medical Informatics, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands. ReynersAKL; Center of Expertise for Palliative Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. van der Linden YM; Center of Expertise in Palliative Care, Leiden University Medical Center, Albinusdreef 2, PO box 9600, 2300 RC, Leiden, The Netherlands.; Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Dec 24; Vol. 12 (1), pp. 22295. Date of Electronic Publication: 2022 Dec 24.
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor.
Autorzy:
Pantaleo MA; Division in Medical Oncology, IRCSS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. . Heinrich MC; Portland VA Health Care System and Oregon Health and Science University, Knight Cancer Institute, Portland, Oregon, USA. Italiano A; Institut Bergonie, Bordeaux, France. Valverde C; Hospital Universitario Vall D Hebron, Medical Oncology, Barcelona, Spain. Schöffski P; Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, and Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium. Grignani G; Division of Medical Oncology, Candiolo Cancer Institute, FPO - IRCCS, St. Provinciale 142, Km 3.95 - 10060, Candiolo, TO, Italy. ReynersAKL; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Bauer S; Department of Medical Oncology, Sarcoma Center, West German Cancer Center and German Consortium for Translational Cancer Research (DKTK), University Hospital Essen, Essen, Germany. Reichardt P; Department of Oncology and Palliative Care Helios Klinikum Berlin Buch, Berlin, Germany. Stark D; Leeds Institute for Medical Research, St James's University Hospital, Leeds, UK. Berhanu G; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Brandt U; Novartis Pharma AG, Basel, Switzerland. Stefanelli T; Novartis Pharma AG, Basel, Switzerland. Gelderblom H; Department of Medical Oncology, Leiden University, Leiden, The Netherlands.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 May 06; Vol. 22 (1), pp. 511. Date of Electronic Publication: 2022 May 06.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Multicenter Study
Evaluating quality of care at the end of life and setting best practice performance standards: a population-based observational study using linked routinely collected administrative databases.
Autorzy:
Oosterveld-Vlug MG; Netherlands Institute for Health Services Research (Nivel), Utrecht, the Netherlands. . Heins MJ; Netherlands Institute for Health Services Research (Nivel), Utrecht, the Netherlands. Boddaert MSA; Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands. Engels Y; Department of Anesthesiology, Pain and Palliative Medicine, Radboud University Medical Center, Nijmegen, the Netherlands. Heide AV; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands. Onwuteaka-Philipsen BD; Department of Public and Occupational Health, Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. ReynersAKL; Department of Medical Oncology, Center of Expertise in Palliative Care, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands. Francke AL; Netherlands Institute for Health Services Research (Nivel), Utrecht, the Netherlands.; Department of Public and Occupational Health, Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
BMC palliative care [BMC Palliat Care] 2022 Apr 12; Vol. 21 (1), pp. 51. Date of Electronic Publication: 2022 Apr 12.
Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases.
Autorzy:
Eggen AC; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.; Expertise Centre Palliative Care, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Hospers GAP; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Bosma I; Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Kramer MCA; Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. ReynersAKL; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.; Expertise Centre Palliative Care, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Jalving M; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Mar 05; Vol. 22 (1), pp. 247. Date of Electronic Publication: 2022 Mar 05.
Subjective Mouthfeel and Temperature Alterations in COVID-19 Patients Six to Ten Months After Diagnosis.
Autorzy:
van Elst JM; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Boesveldt S; Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands. Vissink A; Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Jager-Wittenaar H; Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; Research Group Healthy Ageing, Allied Health Care and Nursing, Hanze University of Applied Sciences, Groningen, The Netherlands. ReynersAKL; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. de Haan JJ; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Pokaż więcej
Źródło:
Chemosensory perception [Chemosens Percept] 2022; Vol. 15 (2), pp. 165-174. Date of Electronic Publication: 2022 Nov 12.
Factors associated with cognitive impairment and cognitive concerns in patients with metastatic non-small cell lung cancer.
Autorzy:
Eggen AC; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Richard NM; Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Bosma I; Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Jalving M; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Leighl NB; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Liu G; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Mah K; Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Higazy R; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Shultz DB; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. ReynersAKL; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Rodin G; Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Edelstein K; Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Pokaż więcej
Źródło:
Neuro-oncology practice [Neurooncol Pract] 2021 Sep 07; Vol. 9 (1), pp. 50-58. Date of Electronic Publication: 2021 Sep 07 (Print Publication: 2022).
Outcomes of ICU patients with and without perceptions of excessive care: a comparison between cancer and non-cancer patients.
Autorzy:
Benoit DD; Department of Intensive Care Medicine, Ghent University Hospital, C. Heymanslaan 10, 9000, Ghent, Belgium. . van der Zee EN; Department of Intensive Care Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands. Darmon M; Hôpital Saint-Louis and University, Paris, France. ReynersAKL; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands. Metaxa V; Department of Critical Care, King's College Hospital, London, UK. Mokart D; Critical Care and Anesthesiology, Institut Paoli Calmettes, Marseille, France. Wilmer A; Department of General Internal Medicine, University Hospital Louvain, Louvain, Belgium. Depuydt P; Department of Intensive Care Medicine, Ghent University Hospital, C. Heymanslaan 10, 9000, Ghent, Belgium. Hvarfner A; Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden. Rusinova K; Department of Palliative Care, 1St Faculty of Medicine, Charles University of Medicine, Prague, Czech Republic. Zijlstra JG; Department of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, Netherlands. Vincent F; Medical Surgical ICU, GHIC Le Raincy-Montfermeil, Montfermeil, France. Lathyris D; Department of Intensive Care Medicine, General Hospital G. Gennimatas, Thessaloniki, Greece. Meert AP; Service de Médecine Interne, Université Libre de Bruxelles (ULB), soins intensifs et urgences oncologiques, Institut Jules Bordet, Brussels, Belgium. Devriendt J; Intensive Care Unit, Brugmann University Hospital, Brussels, Belgium. Uyttersprot E; Department of Applied Mathematics and Computer Sciences, Ghent University, Ghent, Belgium. Kompanje EJO; Department of Intensive Care Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands. Piers R; Department of Geriatric Medicine, Ghent University Hospital, Ghent, Belgium. Azoulay E; Hôpital Saint-Louis and University, Paris, France.
Pokaż więcej
Źródło:
Annals of intensive care [Ann Intensive Care] 2021 Jul 31; Vol. 11 (1), pp. 120. Date of Electronic Publication: 2021 Jul 31.
Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients.
Autorzy:
Leest PV; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. Boonstra PA; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. Elst AT; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. Kempen LCV; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. Tibbesma M; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. Koopmans J; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. Miedema A; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. Tamminga M; Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. Groen HJM; Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. ReynersAKL; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. Schuuring E; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2020 May 13; Vol. 12 (5). Date of Electronic Publication: 2020 May 13.
Gastrointestinal Stromal Tumours (GIST) in Young Adult (18-40 Years) Patients: A Report from the Dutch GIST Registry.
Autorzy:
IJzerman NS; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Drabbe C; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands. den Hollander D; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands. Mohammadi M; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands. van Boven H; Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Desar IME; Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands. Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands. Grünhagen DJ; Department of Surgical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. ReynersAKL; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. van Noesel MM; Department of Solid Tumors, Princess Maxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands. Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Steeghs N; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. van der Graaf WTA; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2020 Mar 20; Vol. 12 (3). Date of Electronic Publication: 2020 Mar 20.
Risk factors of unmet needs among women with breast cancer in the post-treatment phase.
Autorzy:
Lo-Fo-Wong DNN; Academic Medical Center, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands. de Haes HCJM; Academic Medical Center, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands. Aaronson NK; Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands. van Abbema DL; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. den Boer MD; Erasmus MC, Cancer Institute, Rotterdam, The Netherlands. van Hezewijk M; Leiden University Medical Center, Leiden, The Netherlands. Immink M; Reinier de Graaf Hospital, Delft, The Netherlands. Kaptein AA; Leiden University Medical Center, Leiden, The Netherlands. Menke-Pluijmers MBE; Albert Schweitzer Hospital, Dordrecht, The Netherlands. ReynersAKL; University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Russell NS; Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Schriek M; St. Elisabeth Hospital, Tilburg, The Netherlands. Sijtsema S; University Medical Center Utrecht, Utrecht, The Netherlands. van Tienhoven G; Academic Medical Center, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands. Verdam MGE; Academic Medical Center, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands. Sprangers MAG; Academic Medical Center, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
Psycho-oncology [Psychooncology] 2020 Mar; Vol. 29 (3), pp. 539-549. Date of Electronic Publication: 2019 Dec 16.
Typ publikacji:
Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients.
Autorzy:
Verboom MC; Department of Medical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, Netherlands. Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, Netherlands. Kerst JM; Department of Medical Oncology and Clinical Pharmacology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, P.O. Box 90203, 1006 BE Amsterdam, Netherlands. Steeghs N; Department of Medical Oncology and Clinical Pharmacology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, P.O. Box 90203, 1006 BE Amsterdam, Netherlands. ReynersAKL; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30001, 9700 RB Groningen, Netherlands. Sleijfer S; Department of Medical Oncology, Erasmus MC Cancer Institute, P.O. Box 5201, 3008 AE Rotterdam, Netherlands. van der Graaf WTA; Department of Medical Oncology, Radboud University Medical Center, P.O. Box 9101, 6500 HB Nijmegen, Netherlands. van den Hout WB; Department of Medical Decision Making, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, Netherlands.
Pokaż więcej
Źródło:
Sarcoma [Sarcoma] 2019 Jun 02; Vol. 2019, pp. 3234205. Date of Electronic Publication: 2019 Jun 02 (Print Publication: 2019).
Caregivers of patients receiving long-term treatment with a tyrosine kinase inhibitor (TKI) for gastrointestinal stromal tumour (GIST): a cross-sectional assessment of their distress and burden.
Autorzy:
Langenberg SMCH; a Department of Medical Oncology , Radboud University Medical Centre Nijmegen , Nijmegen , The Netherlands. ReynersAKL; b Department of Medical Oncology , University of Groningen, University Medical Centre Groningen , Groningen , The Netherlands. Wymenga ANM; c Department of Medical Oncology , Medical Spectrum Twente , Enschede , The Netherlands. Sieling GCM; b Department of Medical Oncology , University of Groningen, University Medical Centre Groningen , Groningen , The Netherlands. Veldhoven CMM; d Department of Pain and palliatieve care , Radboud University Medical Centre Nijmegen , Nijmegen , The Netherlands.; e General practitioner Berg en Dal , Nijmegen , The Netherlands. van Herpen CML; a Department of Medical Oncology , Radboud University Medical Centre Nijmegen , Nijmegen , The Netherlands. Prins JB; f Department of Medical Psychology , Radboud University Medical Centre Nijmegen , Nijmegen , The Netherlands. van der Graaf WTA; a Department of Medical Oncology , Radboud University Medical Centre Nijmegen , Nijmegen , The Netherlands.; g Division of Clinical Studies, The Institute of Cancer Research & the Sarcoma Unit , Royal Marsden Hospital , London , UK.
Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study.
Autorzy:
Leimkühler M; Department of Surgery, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands. Hemmer PHJ; Department of Surgery, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands. . ReynersAKL; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands. de Groot DJA; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands. van Ginkel RJ; Department of Surgery, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands. Been LB; Department of Surgery, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands. de Bock GH; Department of Epidemiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands. van Leeuwen BL; Department of Surgery, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands. .
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
